CAMP CONTINUATION STUDY/PHASE 2 (CAMPCS/2) PROTOCOL

训练营继续研究/第 2 阶段 (CAMPCS/2) 方案

• 批准号: 7719390
• 负责人: Stanley J Szefler
• 金额: $ 0.42万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719390
• 关键词: Adrenal Cortex Hormones; Age; Breathing; Bronchodilator Agents; Budesonide; Child; Childhood Asthma; Computer Retrieval of Information on Scientific Projects Database; Development; Funding; Grant; Growth; Institution; Intervention Studies; Lung; Nedocromil; Phase; Phase II Clinical Trials; Population Study; Protocols documentation; Randomized; Research; Research Personnel; Resources; Source; Steroids; Time; United States National Institutes of Health; design; programs; treatment duration

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Childhood Asthma Management Program (CAMP) Continuation Study 2 (CAMPCS/2) is a four year extension of an ongoing 10 year study of childhood asthma. The original CAMP study was a 4-6 year study of intervention with either budesonide (an inhaled corticosteroid), nedocromil (a non-steroid), or as need bronchodilator therapy alone in the study population of over 1,000 children ages 5-13 years at the time of randomization. The CAMPCS and CAMPCS/2 study is designed to evaluate the effect of this intense treatment period on maximal lung growth and body development.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 童年哮喘管理计划（CAMP）连续研究2（CAMCCS/2）是一项正在进行的10年童年哮喘研究的四年延长。 最初的CAMP研究是一项4 - 6年的研究研究，对在随机化时在5-13岁以上的研究人群中，仅在1000名儿童的研究人群中，单独使用Budesonide（一种吸入的皮质类固醇），Nededocromil（一种非类固醇），或者是需要支气管扩张剂治疗的4 - 6年研究。 CAMCC和CAMCC/2研究旨在评估此强烈治疗期对最大肺部生长和身体发育的影响。